Loquai Carmen, Dechent Dagmar, Garzarolli Marlene, Kaatz Martin, Kaehler Katharina C, Kurschat Peter, Meiss Frank, Stein Annette, Nashan Dorothee, Micke Oliver, Muecke Ralph, Muenstedt Karsten, Stoll Christoph, Schmidtmann Irene, Huebner Jutta
Department of Dermatology, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.
Institute of Occupational Medicine, University Hospital, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
Med Oncol. 2016 May;33(5):52. doi: 10.1007/s12032-016-0764-6. Epub 2016 Apr 18.
Complementary and alternative medicine (CAM) is used widely among cancer patients. Beside the risk of interaction with cancer therapies, interactions with treatment for comorbidities are an underestimated problem. The aim of this study was to assess prevalence of interactions between CAM and drugs for comorbidities from a large CAM usage survey on melanoma patients and to classify herb-drug interactions with regard to their potential to harm. Consecutive melanoma outpatients of seven skin cancer centers were asked to complete a standardized CAM questionnaire including questions to their CAM use and their taken medication for comorbidities and cancer. Each combination of conventional drugs and complementary substances was evaluated for their potential of interaction. 1089 questionnaires were eligible for evaluation. From these, 61.6% of patients reported taking drugs regularly from which 34.4% used biological-based CAM methods. Risk evaluation for interaction was possible for 180 CAM users who listed the names or substances they took for comorbidities. From those patients, we found 37.2% at risk of interaction of their co-consumption of conventional and complementary drugs. Almost all patients using Chinese herbs were at risk (88.6%). With a high rate of CAM usage at risk of interactions between CAM drugs and drugs taken for comorbidities, implementation of a regular assessment of CAM usage and drugs for comorbidities is mandatory in cancer care.
补充和替代医学（CAM）在癌症患者中广泛使用。除了与癌症治疗相互作用的风险外，与合并症治疗的相互作用是一个被低估的问题。本研究的目的是通过一项关于黑色素瘤患者的大型补充和替代医学使用情况调查，评估补充和替代医学与合并症用药之间相互作用的发生率，并根据其潜在危害对草药-药物相互作用进行分类。七个皮肤癌中心的连续黑色素瘤门诊患者被要求填写一份标准化的补充和替代医学问卷，包括关于他们使用补充和替代医学的情况以及他们用于治疗合并症和癌症的药物的问题。对每种传统药物和补充物质的组合进行相互作用可能性评估。1089份问卷符合评估条件。其中，61.6%的患者报告定期服药，其中34.4%使用基于生物的补充和替代医学方法。对180名列出了治疗合并症所服用药物名称或物质的补充和替代医学使用者进行了相互作用风险评估。在这些患者中，我们发现37.2%的患者在同时服用传统药物和补充药物时有相互作用的风险。几乎所有使用中药的患者都有风险（88.6%）。鉴于补充和替代医学药物与合并症用药之间存在相互作用风险的使用率很高，在癌症护理中定期评估补充和替代医学的使用情况以及合并症用药情况是必不可少的。
